Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Express Scripts
Fuji
US Department of Justice
Fish and Richardson
Dow
Chinese Patent Office
Merck
US Army

Generated: January 18, 2018

DrugPatentWatch Database Preview

TAZORAC Drug Profile

« Back to Dashboard

When do Tazorac patents expire, and when can generic versions of Tazorac launch?

Tazorac is a drug marketed by Allergan and is included in two NDAs.

The generic ingredient in TAZORAC is tazarotene. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the tazarotene profile page.
Drug patent expirations by year for TAZORAC
Pharmacology for TAZORAC
Ingredient-typeRetinoids
Drug ClassRetinoid

US Patents and Regulatory Information for TAZORAC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan TAZORAC tazarotene CREAM;TOPICAL 021184-001 Sep 29, 2000 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-002 Jun 13, 1997 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene CREAM;TOPICAL 021184-002 Sep 29, 2000 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-001 Jun 13, 1997 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for TAZORAC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-001 Jun 13, 1997 ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene CREAM;TOPICAL 021184-001 Sep 29, 2000 ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-002 Jun 13, 1997 ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene CREAM;TOPICAL 021184-002 Sep 29, 2000 ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-002 Jun 13, 1997 ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-001 Jun 13, 1997 ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-001 Jun 13, 1997 ➤ Subscribe ➤ Subscribe
Allergan TAZORAC tazarotene GEL;TOPICAL 020600-002 Jun 13, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Teva
Express Scripts
Covington
Cerilliant
Queensland Health
Novartis
McKinsey
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot